Results 61 to 70 of about 313 (85)

Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects. [PDF]

Acta Pharm Sin B
Lu X, Zhou J, Ming Y, Wang Y, He R, Li Y, Feng L, Zeng B, Du Y, Wang C.   +9 more
europepmc   +1 more source

WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides. [PDF]

Int J Mol Sci
Finkina EI, Shevchenko OV, Gerasimova AA, Fateeva SI, Balandin SV, Ovchinnikova TV.   +5 more
europepmc   +1 more source

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. [PDF]

Antimicrobial Agents and Chemotherapy, 2020
There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of ...
Shakti Singh, Nathan Paul Wiederhold, Teclegiorgis Gebremariam   +2 more
exaly   +7 more sources

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. Manogepix (MGX) is a novel antifungal that targets Gwt1, a protein involved in an early step in the conserved glycosylphosphotidyl ...
Scott G Filler, Nathan Paul Wiederhold, Teclegiorgis Gebremariam   +2 more
exaly   +6 more sources